Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

NCT01649271 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Stomach Neoplasms

Interventions

DRUG: Herceptin
DRUG: afatinib
DRUG: trastuzumab
DRUG: Herceptin
DRUG: afatinib
DRUG: afatinib

Sponsor

Boehringer Ingelheim